Literature DB >> 17710467

Manual aspiration thrombectomy with stent placement: rapid and effective treatment for phlegmasia cerulea dolens with impending venous gangrene.

Levent Oguzkurt1, Fahri Tercan, Ugur Ozkan.   

Abstract

Phlegmasia cerulea dolens is an uncommon but potentially life-threatening complication of acute deep vein thrombosis. It is an emergency and delay in treatment may cause death or loss of the patient's limb. Surgical thrombectomy is the recommended treatment in venous gangrene. Catheter-directed intrathrombus thrombolysis has been reported as successful, but it may require a lengthy infusion. Manual aspiration thrombectomy may clear the entire thrombus with no need for thrombolytic administration and provide rapid and effective treatment for patients with phlegmasia cerulea dolens with impending venous gangrene.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17710467     DOI: 10.1007/s00270-007-9156-9

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  4 in total

1.  Phlegmasia Cerulea Dolens with Compartment Syndrome.

Authors:  Wongsakorn Chaochankit; Osaree Akaraborworn
Journal:  Ann Vasc Dis       Date:  2018-09-25

2.  Successful thrombectomy and thrombolysis of deep vein thrombosis in a patient with acute phlegmasia cerulea dolens with May-Thurner anatomy.

Authors:  John Jensen; Joshua Ladner; Ryan Mann; Charles Kitley
Journal:  Radiol Case Rep       Date:  2021-01-05

3.  Upper Limb Phlegmasia Cerulea Dolens Secondary to Heparin-induced Thrombocytopenia Leading to Gangrene.

Authors:  Anuhya Kommalapati; Avyakta Kallam; Jairam Krishnamurthy; Sri H Tella; Jahnavi Koppala; Pavan Kumar Tandra
Journal:  Cureus       Date:  2018-06-21

4.  Postinterventional antithrombotic management after venous stenting of the iliofemoral tract in acute and chronic thrombosis: A systematic review.

Authors:  Pascale Notten; Hugo Ten Cate; Arina J Ten Cate-Hoek
Journal:  J Thromb Haemost       Date:  2021-01-05       Impact factor: 5.824

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.